

Venous Thromboembolism Prophylaxis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Lower Extremity, Upper Extremity), By End Use (Hospitals & Clinics, Ambulatory care Centers, Others) By Region and Competition

<https://marketpublishers.com/r/V56038FB938EEN.html>

Date: November 2023

Pages: 190

Price: US\$ 4,900.00 (Single User License)

ID: V56038FB938EEN

Abstracts

Global Venous Thromboembolism Prophylaxis Market is anticipated to project robust growth in the forecast period. The Global Venous Thromboembolism (VTE) Prophylaxis Market is a dynamic and rapidly evolving sector within the healthcare industry, driven by the increasing awareness of VTE risk factors and the need for preventive measures. VTE encompasses a spectrum of conditions, including deep vein thrombosis (DVT) and pulmonary embolism (PE), which can have severe consequences, including disability and death. As a result, healthcare providers and pharmaceutical companies are actively engaged in developing and delivering prophylactic solutions to reduce the incidence of VTE.

One of the primary drivers of this market is the growing aging population, as elderly individuals are more susceptible to VTE due to decreased mobility and other risk factors. Additionally, surgeries, especially orthopedic and major surgeries, increase the risk of VTE, further fueling the demand for prophylactic measures. To address this, a range of prophylactic interventions is available, including anticoagulant medications, compression stockings, and mechanical prophylaxis devices. These options offer healthcare providers a variety of tools to tailor VTE prevention strategies to individual patient needs.

The global VTE prophylaxis market is also influenced by technological advancements in

medical devices and pharmaceuticals. Innovations such as novel anticoagulant drugs with improved safety profiles and the development of more comfortable and effective mechanical prophylaxis devices contribute to the market's growth. Moreover, the integration of digital health technologies, such as electronic health records and remote patient monitoring, is enhancing the management and monitoring of VTE prophylaxis, leading to better patient outcomes.

Key Market Drivers

Aging Population

The aging population is a significant driving force behind the growth of the Global Venous Thromboembolism (VTE) Prophylaxis Market. As the world's population continues to age, there is a marked increase in the incidence of VTE-related health issues, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Elderly individuals are particularly vulnerable to VTE due to factors like reduced mobility, comorbidities, and alterations in blood composition. With the aging demographic, there is a heightened demand for effective VTE prophylactic measures.

One of the primary reasons for this increased demand is the higher prevalence of surgical procedures among older individuals. Surgical interventions, especially orthopedic and major surgeries, are known risk factors for VTE. The elderly population frequently undergoes joint replacements, cardiac surgeries, and other medical interventions, putting them at greater risk. Healthcare providers are acutely aware of this risk and are increasingly implementing prophylactic strategies, such as anticoagulant medications and mechanical devices, to minimize the likelihood of VTE in their elderly patients.

Furthermore, the elderly population's vulnerability to VTE is exacerbated by their decreased mobility and lifestyle changes. Reduced physical activity and prolonged periods of immobility, such as extended bed rest or long flights, can significantly elevate the risk of blood clots. As the aging population seeks to maintain their mobility and quality of life, the demand for VTE prophylaxis becomes even more critical.

Pharmaceutical companies have responded to this growing need by developing anticoagulant medications with improved safety profiles and dosing regimens suitable for older patients. Additionally, medical device manufacturers have introduced more comfortable and efficient mechanical prophylaxis devices, ensuring that VTE prevention options are well-suited for elderly individuals.

Increasing Surgical Procedures

Surgical procedures have played a pivotal role in driving the growth of the Global Venous Thromboembolism (VTE) Prophylaxis Market. VTE, encompassing conditions like deep vein thrombosis (DVT) and pulmonary embolism (PE), poses a significant risk to patients undergoing surgery, making prophylaxis a vital component of perioperative care. This imperative need for VTE prevention has led to the expansion of the prophylaxis market.

Orthopedic and major surgeries, in particular, carry a heightened risk of VTE due to several factors. Patients undergoing joint replacements, spinal surgeries, or cardiac procedures often experience reduced mobility during their recovery, which increases the likelihood of blood clot formation. Moreover, the trauma inflicted on blood vessels during surgery can further elevate VTE risk. Healthcare providers are acutely aware of these risks and are increasingly adopting stringent VTE prevention strategies to safeguard their patients.

Anticoagulant medications and mechanical prophylaxis devices are cornerstones of VTE prevention in surgical settings. Pharmaceutical companies have introduced newer anticoagulants with improved safety profiles and dosing regimens, offering healthcare providers more flexibility in tailoring VTE prevention strategies to individual patient needs. Concurrently, mechanical devices, such as intermittent pneumatic compression (IPC) pumps and compression stockings, have evolved to become more comfortable, efficient, and patient-friendly, contributing to the overall effectiveness of mechanical prophylaxis. The rising number of surgical procedures worldwide, driven by factors such as population growth, an aging demographic, and advancements in medical technology, directly contributes to the rise in demand for Global Venous Thromboembolism (VTE) Prophylaxis Market.

Technological Advancements

Technological advancements have emerged as a pivotal driver behind the remarkable growth of the Global Venous Thromboembolism (VTE) Prophylaxis Market. These advancements have not only improved the efficacy of VTE prevention but have also enhanced patient comfort and safety, propelling the market forward.

One notable area of technological progress is the development of advanced anticoagulant medications. Pharmaceutical companies have introduced novel oral

anticoagulants (NOACs) that offer improved safety profiles and dosing regimens compared to traditional anticoagulants like warfarin. NOACs require less monitoring and have fewer dietary restrictions, making them more patient-friendly. This technological innovation provides healthcare providers with more options for tailoring VTE prevention strategies to individual patient needs, driving the market's growth.

In the realm of mechanical prophylaxis, significant strides have been made in the design and functionality of devices aimed at preventing VTE. Intermittent pneumatic compression (IPC) devices, for instance, have become more comfortable, portable, and user-friendly. Patients can now wear them with greater ease, and healthcare providers can adjust settings more precisely to meet specific patient requirements. These advancements have not only increased patient compliance but also contributed to the overall effectiveness of mechanical prophylaxis in preventing VTE.

Moreover, the integration of digital health technologies has revolutionized VTE prevention. Electronic health records (EHRs) enable healthcare providers to access patient histories and risk factors rapidly, facilitating timely VTE prophylaxis decisions. Remote patient monitoring systems allow for continuous surveillance, enabling early detection of potential VTE events and immediate intervention. This real-time data exchange ensures that patients receive the appropriate preventive care, significantly reducing the incidence of VTE.

Innovation in diagnostic tools has also played a role in advancing VTE prophylaxis. Advanced imaging techniques, such as ultrasound and CT angiography, have improved the detection and diagnosis of VTE, allowing healthcare providers to identify at-risk patients more accurately. This leads to better-informed decisions regarding prophylactic measures, further strengthening the market.

Key Market Challenges

Cost of Prophylaxis

The price tag associated with VTE prevention, especially in the case of anticoagulant medications and mechanical devices, can be overwhelming for both healthcare systems and patients. This becomes particularly evident in regions with limited healthcare budgets or in countries where out-of-pocket expenses for medical treatments are high. Such expenses can deter individuals from seeking prophylactic measures, even when they are at risk of developing VTE.

Anticoagulant medications, while effective, often come with a high cost, especially the newer, more advanced drugs with better safety profiles and fewer side effects. For many patients, these medications need to be taken long-term, leading to escalating costs over time. Additionally, mechanical prophylaxis devices, such as intermittent pneumatic compression (IPC) pumps or advanced compression stockings, can also be pricey. While these devices are vital for patients who cannot take anticoagulants due to contraindications, their costs can be a significant barrier to widespread adoption.

Furthermore, the financial implications of VTE prophylaxis are not limited to the direct cost of medications and devices. Monitoring patients, especially those on anticoagulant medications, requires regular blood tests and follow-ups, incurring additional expenses. For many patients, especially those without comprehensive insurance coverage, these cumulative costs can be daunting.

Risk Assessment and Stratification

Effective risk assessment and stratification are essential components of preventing Venous Thromboembolism (VTE), a condition characterized by the formation of blood clots that can lead to deep vein thrombosis (DVT) or pulmonary embolism (PE). However, despite their critical importance, these processes present substantial challenges for the Global VTE Prophylaxis Market.

One of the primary challenges is accurately assessing a patient's risk of developing VTE. Risk assessment involves evaluating various factors such as a patient's age, medical history, comorbidities, and surgical procedures. However, these risk factors are often interconnected and can vary from patient to patient, making it challenging to establish a standardized and universally applicable risk assessment tool.

Another obstacle is the proper stratification of patients into different risk categories. While risk assessment identifies high-risk individuals, stratification is the process of determining the most suitable prophylactic measures for each patient based on their risk level. Achieving accurate stratification is complicated by the lack of consensus on risk categories and the absence of clear guidelines for tailoring prophylaxis accordingly.

Additionally, some patients may have multiple risk factors that further complicate the risk assessment process. For example, an elderly patient undergoing major surgery may have both age-related risk factors and surgical risk factors. Deciding which factors should take precedence and how to adjust prophylactic measures accordingly can be a complex and challenging task.

Key Market Trends

Digital Health Integration

Digital health integration is emerging as a pivotal driver behind the growth of the Global Venous Thromboembolism (VTE) Prophylaxis Market. VTE, a condition characterized by the formation of blood clots in deep veins, poses a significant health risk, especially in patients undergoing surgery or experiencing extended periods of immobility. The integration of digital health technologies is revolutionizing the way VTE prophylaxis is managed, leading to more effective prevention and improved patient outcomes.

Electronic health records (EHRs) are a cornerstone of digital health integration in VTE prophylaxis. They enable healthcare providers to access patient histories, risk factors, and medication profiles quickly and accurately. This real-time access to patient data facilitates timely risk assessment, ensuring that high-risk patients receive the appropriate prophylactic measures.

Moreover, remote patient monitoring systems are playing a vital role in enhancing VTE prevention. These systems allow healthcare providers to continuously monitor patients, even after they leave the hospital or clinical setting. By remotely tracking patient activity, vital signs, and medication adherence, healthcare teams can detect early warning signs of VTE development and intervene promptly. This level of surveillance significantly reduces the incidence of VTE and improves patient safety.

Telemedicine and telehealth platforms are also contributing to digital health integration in VTE prophylaxis. These platforms enable healthcare providers to conduct virtual consultations with patients, assess their risk factors, and provide guidance on prophylactic measures. This remote access to healthcare expertise enhances patient education and engagement, further promoting VTE prevention.

Artificial intelligence (AI) and machine learning are increasingly being utilized to analyze vast datasets related to VTE risk factors and patient profiles. These technologies can identify patterns and risk factors that may not be immediately evident to healthcare providers. AI-driven predictive analytics assist in more accurate risk assessment and stratification, ensuring that prophylactic measures are tailored to each patient's unique needs.

Advancements in Pharmaceutical Solutions

Advancements in pharmaceutical solutions have played a pivotal role in boosting the Global Venous Thromboembolism (VTE) Prophylaxis Market. VTE, a condition characterized by the formation of blood clots in deep veins, presents a significant health risk, especially in surgical and immobile patients. Pharmaceutical innovations have revolutionized the prevention and management of VTE, making prophylaxis more effective and patient friendly.

One of the most notable advancements is the development of novel oral anticoagulants (NOACs). These medications represent a major breakthrough in VTE prophylaxis, offering improved safety profiles and dosing regimens compared to traditional anticoagulants like warfarin. NOACs require less frequent monitoring and have fewer dietary restrictions, making them more patient-friendly and suitable for a broader range of individuals. Their ease of use and reduced risk of complications have significantly contributed to their adoption and the overall growth of the VTE prophylaxis market.

Furthermore, pharmaceutical companies are investing in the development of anticoagulant medications specifically tailored to the needs of surgical and high-risk patients. These medications are designed to provide effective VTE prevention without increasing the risk of bleeding complications, which is a critical consideration in prophylaxis. These advancements allow healthcare providers to customize prophylactic strategies for each patient, optimizing their safety and reducing the incidence of VTE.

The introduction of longer-acting anticoagulants has also enhanced VTE prophylaxis. Some medications now offer extended protection against clot formation, reducing the need for frequent dosing and monitoring. This not only improves patient convenience but also ensures continuous coverage during the high-risk period after surgery or during immobility. Additionally, pharmaceutical companies are continuously working to develop more targeted prophylactic medications based on patient risk factors and specific surgical procedures. This personalized medicine approach allows for the tailoring of prophylactic measures to individual patient needs, increasing the overall effectiveness of VTE prevention.

Segmental Insights

Type Insights

Based on the Type, the Lower Extremity emerged as the dominant segment in the global market for Global Venous Thromboembolism Prophylaxis Market in 2022. Lower

extremity surgeries, which include procedures like hip and knee replacements, are more common than upper extremity surgeries. These surgeries often involve more extensive tissue trauma and longer periods of immobility, which significantly increase the risk of VTE. Consequently, the larger number of lower extremity surgeries leads to a higher demand for VTE prophylaxis in this category.

End Use Insights

Based on the End Use, the Hospitals & Clinics segment emerged as the dominant player in the global market for Global Venous Thromboembolism Prophylaxis Market in 2022. Hospitals are the primary institutions where major surgeries and medical procedures take place. They handle a significantly larger volume of surgical cases compared to ambulatory care centers. Many of these surgeries, such as joint replacements, cardiac surgeries, and abdominal procedures, are associated with a higher risk of VTE. Consequently, the sheer number of surgical procedures conducted in hospitals generates a substantial demand for VTE prophylaxis.

Regional Insights

North America emerged as the dominant player in the global Venous Thromboembolism Prophylaxis Market in 2022, holding the largest market share. North America boasts a highly developed healthcare infrastructure with state-of-the-art facilities, well-trained medical professionals, and advanced medical technologies. This advanced healthcare system is well-equipped to diagnose and manage VTE, driving the demand for VTE prophylaxis products and services. The region experiences a significant volume of surgical procedures, including orthopedic surgeries, cardiovascular procedures, and abdominal surgeries. These surgeries often carry an elevated risk of VTE, leading to a substantial demand for prophylactic measures.

Key Market Players

Arjo

Encompass Group

Argon Medical Devices

MEGO AFEK

Zenith Technical Innovations

Cook Medical

Bio Compression Systems

ThermoTek USA

Boston Scientific Corporation

Cardinal Health (Medtronic)

Report Scope:

In this report, the Global Venous Thromboembolism Prophylaxis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Venous Thromboembolism Prophylaxis Market, By Type:

Lower Extremity

Upper Extremity

Global Venous Thromboembolism Prophylaxis Market, By End Use:

Hospitals & Clinics

Ambulatory care Centers

Others

Global Venous Thromboembolism Prophylaxis Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Turkey

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Venous Thromboembolism Prophylaxis Market.

Available Customizations:

Global Venous Thromboembolism Prophylaxis Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. GLOBAL VENOUS THROMBOEMBOLISM PROPHYLAXIS MARKET OUTLOOK

- 4.1. Market Size & Forecast
 - 4.1.1. By Value
- 4.2. Market Share & Forecast
 - 4.2.1. By Type (Lower Extremity, Upper Extremity)
 - 4.2.2. By End Use (Hospitals & Clinics, Ambulatory care Centers, Others)
 - 4.2.3. By Company (2022)
- 4.3. Market Map
 - 4.3.1. By Type
 - 4.3.2. By End Use

4.3.3. By Region

5. ASIA PACIFIC VENOUS THROMBOEMBOLISM PROPHYLAXIS MARKET OUTLOOK

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Type

5.2.2. By End Use

5.2.3. By Country

5.3. Asia Pacific: Country Analysis

5.3.1. China Venous Thromboembolism Prophylaxis Market Outlook

5.3.1.1. Market Size & Forecast

5.3.1.1.1. By Value

5.3.1.2. Market Share & Forecast

5.3.1.2.1. By Type

5.3.1.2.2. By End Use

5.3.2. India Venous Thromboembolism Prophylaxis Market Outlook

5.3.2.1. Market Size & Forecast

5.3.2.1.1. By Value

5.3.2.2. Market Share & Forecast

5.3.2.2.1. By Type

5.3.2.2.2. By End Use

5.3.3. Australia Venous Thromboembolism Prophylaxis Market Outlook

5.3.3.1. Market Size & Forecast

5.3.3.1.1. By Value

5.3.3.2. Market Share & Forecast

5.3.3.2.1. By Type

5.3.3.2.2. By End Use

5.3.4. Japan Venous Thromboembolism Prophylaxis Market Outlook

5.3.4.1. Market Size & Forecast

5.3.4.1.1. By Value

5.3.4.2. Market Share & Forecast

5.3.4.2.1. By Type

5.3.4.2.2. By End Use

5.3.5. South Korea Venous Thromboembolism Prophylaxis Market Outlook

5.3.5.1. Market Size & Forecast

5.3.5.1.1. By Value

5.3.5.2. Market Share & Forecast

5.3.5.2.1. By Type

5.3.5.2.2. By End Use

6. EUROPE VENOUS THROMBOEMBOLISM PROPHYLAXIS MARKET OUTLOOK

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Type

6.2.2. By End Use

6.2.3. By Country

6.3. Europe: Country Analysis

6.3.1. France Venous Thromboembolism Prophylaxis Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Type

6.3.1.2.2. By End Use

6.3.2. Germany Venous Thromboembolism Prophylaxis Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Type

6.3.2.2.2. By End Use

6.3.3. Spain Venous Thromboembolism Prophylaxis Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Type

6.3.3.2.2. By End Use

6.3.4. Italy Venous Thromboembolism Prophylaxis Market Outlook

6.3.4.1. Market Size & Forecast

6.3.4.1.1. By Value

6.3.4.2. Market Share & Forecast

6.3.4.2.1. By Type

6.3.4.2.2. By End Use

6.3.5. United Kingdom Venous Thromboembolism Prophylaxis Market Outlook

6.3.5.1. Market Size & Forecast

6.3.5.1.1. By Value

6.3.5.2. Market Share & Forecast

6.3.5.2.1. By Type

6.3.5.2.2. By End Use

7. NORTH AMERICA VENOUS THROMBOEMBOLISM PROPHYLAXIS MARKET OUTLOOK

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Type

7.2.2. By End Use

7.2.3. By Country

7.3. North America: Country Analysis

7.3.1. United States Venous Thromboembolism Prophylaxis Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Type

7.3.1.2.2. By End Use

7.3.2. Mexico Venous Thromboembolism Prophylaxis Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Type

7.3.2.2.2. By End Use

7.3.3. Canada Venous Thromboembolism Prophylaxis Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Type

7.3.3.2.2. By End Use

8. SOUTH AMERICA VENOUS THROMBOEMBOLISM PROPHYLAXIS MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Type

8.2.2. By End Use

8.2.3. By Country

8.3. South America: Country Analysis

8.3.1. Brazil Venous Thromboembolism Prophylaxis Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Type

8.3.1.2.2. By End Use

8.3.2. Argentina Venous Thromboembolism Prophylaxis Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Type

8.3.2.2.2. By End Use

8.3.3. Colombia Venous Thromboembolism Prophylaxis Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Type

8.3.3.2.2. By End Use

9. MIDDLE EAST AND AFRICA VENOUS THROMBOEMBOLISM PROPHYLAXIS MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Type

9.2.2. By End Use

9.2.3. By Country

9.3. MEA: Country Analysis

9.3.1. South Africa Venous Thromboembolism Prophylaxis Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Type

- 9.3.1.2.2. By End Use
- 9.3.2. Saudi Arabia Venous Thromboembolism Prophylaxis Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Type
 - 9.3.2.2.2. By End Use
- 9.3.3. UAE Venous Thromboembolism Prophylaxis Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Type
 - 9.3.3.2.2. By End Use
- 9.3.4. Egypt Venous Thromboembolism Prophylaxis Market Outlook
 - 9.3.4.1. Market Size & Forecast
 - 9.3.4.1.1. By Value
 - 9.3.4.2. Market Share & Forecast
 - 9.3.4.2.1. By Type
 - 9.3.4.2.2. By End Use

10. MARKET DYNAMICS

- 10.1. Drivers
- 10.2. Challenges

11. MARKET TRENDS & DEVELOPMENTS

- 11.1. Recent Developments
- 11.2. Product Launches
- 11.3. Mergers & Acquisitions

12. GLOBAL VENOUS THROMBOEMBOLISM PROPHYLAXIS MARKET: SWOT ANALYSIS

13. PORTER'S FIVE FORCES ANALYSIS

- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers

- 13.4. Power of Customers
- 13.5. Threat of Substitute Product

14. COMPETITIVE LANDSCAPE

- 14.1. Arjo
 - 14.1.1. Business Overview
 - 14.1.2. Company Snapshot
 - 14.1.3. Products & Services
 - 14.1.4. Current Capacity Analysis
 - 14.1.5. Financials (In case of listed)
 - 14.1.6. Recent Developments
 - 14.1.7. SWOT Analysis
- 14.2. Encompass Group
- 14.3. Argon Medical Devices
- 14.4. MEGO AFEK
- 14.5. Zenith Technical Innovations
- 14.6. Cook Medical
- 14.7. Bio Compression Systems
- 14.8. ThermoTek USA
- 14.9. Boston Scientific Corporation
- 14.10. Cardinal Health (Medtronic)

15. STRATEGIC RECOMMENDATIONS

16. ABOUT US & DISCLAIMER

I would like to order

Product name: Venous Thromboembolism Prophylaxis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Lower Extremity, Upper Extremity), By End Use (Hospitals & Clinics, Ambulatory care Centers, Others) By Region and Competition

Product link: <https://marketpublishers.com/r/V56038FB938EEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V56038FB938EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970